<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: Additional ", fill: "#ffddf4"},
{source: "2: Additional ", target: "2: uncertainties", fill: "#ffddf4"},
{source: "2: uncertainties", target: "2: presently known", fill: "#ffddf4"},
{source: "2: presently known", target: "2: immaterial may also affect", fill: "#ffddf4"},
{source: "2: Additional ", target: "6: highly competitive", fill: "#507d2a"},
{source: "6: highly competitive", target: "6: characterized by frequent product improvements", fill: "#507d2a"},
{source: "6: characterized by frequent product improvements", target: "6: evolving technology", fill: "#507d2a"},
{source: "6: highly competitive", target: "8: development", fill: "#483c32"},
{source: "8: development", target: "8: innovative new products by", fill: "#483c32"},
{source: "8: innovative new products by", target: "8: competitors", fill: "#483c32"},
{source: "8: competitors", target: "8: discovery", fill: "#483c32"},
{source: "8: discovery", target: "8: alternative", fill: "#483c32"},
{source: "8: alternative", target: "8: treatments", fill: "#483c32"},
{source: "8: treatments", target: "8: potential cures", fill: "#483c32"},
{source: "8: potential cures", target: "8: conditions", fill: "#483c32"},
{source: "8: conditions", target: "8: products treat could", fill: "#483c32"},
{source: "8: products treat could", target: "8: products noncompetitive", fill: "#483c32"},
{source: "8: development", target: "10: Additionally ", fill: "#a67b5b"},
{source: "10: Additionally ", target: "10: competitors", fill: "#a67b5b"},
{source: "10: competitors", target: "10: greater financial research", fill: "#a67b5b"},
{source: "10: greater financial research", target: "10: development manufacturing", fill: "#a67b5b"},
{source: "10: development manufacturing", target: "10: marketing resources than", fill: "#a67b5b"},
{source: "10: Additionally ", target: "15: depends on", fill: "#900"},
{source: "15: depends on", target: "15: market effectively", fill: "#900"},
{source: "15: market effectively", target: "15: healthcare products", fill: "#900"},
{source: "15: healthcare products", target: "15: sleep clinics", fill: "#900"},
{source: "15: depends on", target: "21: We ", fill: "#002fa7"},
{source: "21: We ", target: "21: Contents ", fill: "#002fa7"},
{source: "21: Contents ", target: "21: cannot assure", fill: "#002fa7"},
{source: "21: cannot assure", target: "21: sleep clinic physicians will continue", fill: "#002fa7"},
{source: "21: sleep clinic physicians will continue", target: "21: home healthcare dealers", fill: "#002fa7"},
{source: "21: home healthcare dealers", target: "21: patients will", fill: "#002fa7"},
{source: "21: patients will", target: "21: substitute competing products", fill: "#002fa7"},
{source: "21: substitute competing products", target: "21: prescription specifying", fill: "#002fa7"},
{source: "21: prescription specifying", target: "21: been written", fill: "#002fa7"},
{source: "21: We ", target: "26: regulatory", fill: "#a32638"},
{source: "26: regulatory", target: "26: environments", fill: "#a32638"},
{source: "26: environments", target: "26: adversely", fill: "#a32638"},
{source: "26: regulatory", target: "38: recent acquisitions with", fill: "#00f"},
{source: "38: recent acquisitions with", target: "38: operations", fill: "#00f"},
{source: "38: operations", target: "38: could suffer", fill: "#00f"},
{source: "38: recent acquisitions with", target: "55: which reimbursement", fill: "#9c2542"},
{source: "55: which reimbursement", target: "55: organizations", fill: "#9c2542"},
{source: "55: which reimbursement", target: "57: Therefore ", fill: "#808000"},
{source: "57: Therefore ", target: "57: reimbursement will", fill: "#808000"},
{source: "57: reimbursement will", target: "57: reimbursement amount", fill: "#808000"},
{source: "57: reimbursement amount", target: "57: initially adequate will", fill: "#808000"},
{source: "57: initially adequate will", target: "57: subsequently", fill: "#808000"},
{source: "57: Therefore ", target: "59: Australia and the United Kingdom ", fill: "#ffe4c4"},
{source: "59: Australia and the United Kingdom ", target: "59: reimbursement", fill: "#ffe4c4"},
{source: "59: reimbursement", target: "59: conditions", fill: "#ffe4c4"},
{source: "59: Australia and the United Kingdom ", target: "64: regulations", fill: "#72a0c1"},
{source: "64: regulations", target: "64: governmental reimbursement programs particularly", fill: "#72a0c1"},
{source: "64: governmental reimbursement programs particularly", target: "64: Medicaid and Medicare", fill: "#72a0c1"},
{source: "64: regulations", target: "START_HERE", fill: "#72a0c1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_Mathematics">Additional Mathematics</a></td>
      <td>Additional Mathematics is a qualification in mathematics, commonly taken by students in high-school (or GCSE exam takers in the United Kingdom). It is applied to a range of problems set out in a different format and wider content to the standard Mathematics at the same level.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Superintendent_of_police_(India)">Superintendent of police (India)</a></td>
      <td>Superintendent of police or SP is a senior rank in Indian Police Service or IPS. Superintendent of Police in Hindi means पुलिस अधीक्षक. They have one Star and one Ashoka emblem on their shoulders and below IPS is written.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_director_general_of_police">Additional director general of police</a></td>
      <td>Additional Director General of Police (ADGP) is an Indian Police Service rank. Though having the maximum possible 3-star police rank just like Director General of Police,  ADGP's are considered same to DGP's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_member_system">Additional member system</a></td>
      <td>The additional member system (AMS) is a mixed electoral system under which most representatives are elected in single-member districts (SMDs), and the other "additional members" are elected to make the seat distribution in the chamber more proportional to the way votes are cast for party lists. It is distinct from parallel voting (also known as the supplementary member system) in that the "additional member" seats are awarded to parties taking into account seats won in SMDs (referred to as compensation or "top-up"), which is not done under parallel voting (a non-compensatory method).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Latin_Extended_Additional">Latin Extended Additional</a></td>
      <td>Latin Extended Additional is a Unicode block.\nThe characters in this block are mostly precomposed combinations of Latin letters with one or more general diacritical marks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Order_of_Australia">Order of Australia</a></td>
      <td>The Order of Australia is an honour that recognises Australian citizens and other persons for outstanding achievement and service. It was established on 14 February 1975 by Elizabeth II, Queen of Australia, on the advice of the Australian Government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Standards_on_Auditing">International Standards on Auditing</a></td>
      <td>International Standards on Auditing (ISA) are professional standards for the auditing of financial information. These standards are issued by the International Auditing and Assurance Standards Board (IAASB).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Insomnia">Insomnia</a></td>
      <td>An insignia (from Latin  insignia, plural of insigne 'emblem, symbol, ensign') is a sign or mark distinguishing a group, grade, rank, or function. It can be a symbol of personal power or that of an official group or governing body.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Certified_Medical_Reimbursement_Specialist">Certified Medical Reimbursement Specialist</a></td>
      <td>Certified Medical Reimbursement Specialist (CMRS) is a voluntary national credential that was created specifically for the medical billing professional. The American Medical Billing Association (AMBA) has been providing this industry certification and designation for nearly a decade.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RESMED INC      ITEM 1A RISK FACTORS          Before deciding to purchase, hold or sell our <font color="blue">common stock</font>, you should     <font color="blue">carefully</font>  consider the risks described below in addition to the other     <font color="blue">cautionary</font>  statements  and  risks  <font color="blue">described elsewhere</font>, and the other     information contained, in this Report and in our other <font color="blue">filings with</font> the SEC,     including  our subsequent reports on Forms 10-Q and 8-K The risks and     <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only ones we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that we currently deem     <font color="blue">immaterial may also affect</font> our business</td>
    </tr>
    <tr>
      <td>If any of these known or unknown     risks or <font color="blue">uncertainties</font> actually occurs with material <font color="blue">adverse effects on us</font>,     our  business,  <font color="blue">financial condition</font> and results of <font color="blue"><font color="blue">operations</font> could</font> be     <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>In that event, the <font color="blue">market price</font> for our <font color="blue">common stock</font> will     <font color="blue">likely decline</font>, and you may lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">inability</font>  to  compete  <font color="blue">successfully</font>  in our <font color="blue">markets may harm</font> our     business</td>
    </tr>
    <tr>
      <td>The markets for our sleep-disordered breathing products are     <font color="blue">highly competitive</font> and are <font color="blue">characterized by frequent product improvements</font>     and <font color="blue">evolving technology</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">successfully</font> depends, in     part, on our ability to develop, <font color="blue">manufacture</font> and <font color="blue">market innovative new</font>     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue"><font color="blue">innovative <font color="blue">new products</font></font> by</font> our <font color="blue">competitors</font> or     the  <font color="blue">discovery</font>  of  <font color="blue">alternative</font>  <font color="blue">treatments</font> or <font color="blue">potential cures</font> for the     <font color="blue">conditions</font> that our <font color="blue"><font color="blue">products treat</font> could</font> make our <font color="blue">products noncompetitive</font> or     obsolete</td>
    </tr>
    <tr>
      <td>Current <font color="blue">competitors</font>, new entrants, academics, and others are     trying  to  develop  new devices, <font color="blue">alternative</font> <font color="blue">treatments</font> or cures, and     <font color="blue">pharmaceutical solutions</font> to the <font color="blue">conditions</font> our <font color="blue">products treat</font></td>
    </tr>
    <tr>
      <td>Additionally, some of our <font color="blue">competitors</font> have greater financial, research and     <font color="blue">development</font>, <font color="blue">manufacturing</font> and <font color="blue">marketing resources than</font> we do</td>
    </tr>
    <tr>
      <td>The past     <font color="blue">several years</font> have seen a <font color="blue">trend towards consolidation</font> in the healthcare     industry and in the markets for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Industry </font><font color="blue">consolidation could</font>     result in <font color="blue">greater competition</font> if our <font color="blue">competitors</font> combine their resources or     if our <font color="blue">competitors</font> are acquired by other <font color="blue">companies with greater resources</font>     than ours</td>
    </tr>
    <tr>
      <td>This <font color="blue">competition <font color="blue">could increase</font> pressure on us</font> to reduce the     <font color="blue">selling prices</font> of our products or could cause us to increase our <font color="blue">spending on</font>     research  and <font color="blue">development</font> and sales and marketing</td>
    </tr>
    <tr>
      <td>If we are unable to     develop <font color="blue">innovative <font color="blue">new products</font></font>, maintain <font color="blue">competitive pricing</font>, and offer     products  that  consumers  perceive  to be <font color="blue">as reliable as</font> those of our     <font color="blue">competitors</font>, our sales or gross <font color="blue">margins could decrease which would harm</font> our     business</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends on</font> our ability to <font color="blue">market <font color="blue"><font color="blue">effective</font>ly</font></font> to dealers of home     <font color="blue">healthcare products</font> and <font color="blue">sleep clinics</font></td>
    </tr>
    <tr>
      <td>We market our <font color="blue">products primarily</font>     to <font color="blue"><font color="blue">home healthcare</font> dealers</font> and to <font color="blue">sleep clinics</font> that diagnose OSA and other     <font color="blue">sleep disorders</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue"><font color="blue">home healthcare</font> dealers</font> and <font color="blue">sleep clinics</font>     play a <font color="blue"><font color="blue">significant</font> role</font> in determining which brand of product a <font color="blue">patient will</font>     use</td>
    </tr>
    <tr>
      <td>The  success  of  our  business <font color="blue">depends on</font> our ability to market     <font color="blue"><font color="blue">effective</font>ly</font> to <font color="blue"><font color="blue">home healthcare</font> dealers</font> and <font color="blue">sleep clinics</font> to ensure that our     products are <font color="blue">properly marketed</font> and sold by these <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have limited resources to market to <font color="blue">approximately</font> the 3cmam000 US sleep     clinics and the more than 6cmam000 <font color="blue">home healthcare</font> dealer branch locations,     most  of  which  use, sell or <font color="blue">recommend several brands</font> of products</td>
    </tr>
    <tr>
      <td>In     addition,  <font color="blue"><font color="blue">home healthcare</font> dealers</font> have experienced <font color="blue">price pressures as</font>     <font color="blue">government</font> and third-party <font color="blue">reimbursement</font> has declined for <font color="blue">home healthcare</font>     products, and <font color="blue"><font color="blue">home healthcare</font> dealers</font> are requiring <font color="blue">price discounts</font> and     <font color="blue">longer periods</font> of time to pay for <font color="blue">products purchased from us</font></td>
    </tr>
    <tr>
      <td>We                                         - 21 -     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font><font color="blue">cannot assure</font> you that <font color="blue">sleep clinic physicians will continue</font> to prescribe     our  products,  or  that  <font color="blue"><font color="blue">home healthcare</font> dealers</font> or <font color="blue">patients will</font> not     <font color="blue">substitute competing products</font> when a <font color="blue">prescription specifying</font> our products     has <font color="blue">been written</font></td>
    </tr>
    <tr>
      <td>We have expanded our <font color="blue">marketing <font color="blue">activities</font></font> to target the <font color="blue">population with</font> a     <font color="blue">predisposition</font>  to  sleep-disordered breathing as well as primary care     physicians and <font color="blue">various medical specialists</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these     <font color="blue"><font color="blue">marketing efforts</font> will</font> be successful in <font color="blue">increasing awareness</font> or sales of our     products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to <font color="blue">market <font color="blue"><font color="blue">effective</font>ly</font></font> our <font color="blue">products outside</font> the US could     impact our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>half our revenues are generated     outside the US, in over 67 <font color="blue">different</font> countries</td>
    </tr>
    <tr>
      <td>Many of these countries     have  unique  <font color="blue">regulatory</font>, medical and business <font color="blue">environments</font>, which may     <font color="blue">adversely</font> impact our ability to market our products</td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">market <font color="blue"><font color="blue">effective</font>ly</font></font> our <font color="blue">products outside</font> the US, our <font color="blue">overall financial</font>     <font color="blue">performance could decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in <font color="blue">foreign currency</font> exchange rates could result in declines in     our reported sales and earnings</td>
    </tr>
    <tr>
      <td>Since our <font color="blue"><font color="blue">international</font> sales</font> and a     <font color="blue">significant</font> portion of our <font color="blue"><font color="blue">manufacturing</font> costs</font> are <font color="blue">denominated</font> in local     currencies and not in US dollars, our reported sales and earnings are     subject to <font color="blue"><font color="blue">fluctuation</font>s</font> in <font color="blue">foreign exchange rates</font></td>
    </tr>
    <tr>
      <td>We had <font color="blue">foreign currency</font>     <font color="blue">transaction losses</font> in <font color="blue">recent periods</font> and may have <font color="blue">further losses</font> in the     future</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue"><font color="blue">international</font> sales</font> will continue to be a <font color="blue">significant</font>     portion of our business and that a <font color="blue">significant</font> portion of our <font color="blue">manufacturing</font>     <font color="blue">costs will continue</font> to be <font color="blue">denominated</font> in <font color="blue">Australian </font>dollars</td>
    </tr>
    <tr>
      <td>If  we  are unable to support our <font color="blue">continued growth</font>, our business could     suffer</td>
    </tr>
    <tr>
      <td>As we continue     to grow, the <font color="blue">complexity</font> of our <font color="blue">operations</font> increases, placing greater demands     on our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our ability to manage our growth <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">depends on</font>     our  ability  to  implement  and  improve our financial and <font color="blue">management</font>     information <font color="blue">systems on</font> a <font color="blue">timely basis</font> and to effect other changes in our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Unexpected </font><font color="blue"><font color="blue">difficult</font>ies during expansion</font>, the failure to attract     and retain <font color="blue">qualified employees</font>, the failure to <font color="blue">successfully</font> replace or     upgrade our <font color="blue">management</font> information systems, the failure to <font color="blue">manage costs</font> or     our <font color="blue">inability</font> to respond <font color="blue"><font color="blue">effective</font>ly</font> to growth or plan for <font color="blue">future expansion</font>     could  cause  our growth to stop</td>
    </tr>
    <tr>
      <td>If we fail to manage <font color="blue"><font color="blue">effective</font>ly</font> and     <font color="blue">efficiently</font> our growth, our <font color="blue">costs <font color="blue">could increase</font> faster than</font> our revenues     and our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If we fail to integrate our <font color="blue"><font color="blue">recent <font color="blue">acquisitions</font></font> with</font> our <font color="blue">operations</font>, our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We are currently in the process of     <font color="blue">integrating</font> our <font color="blue">operations</font> with these <font color="blue">recent <font color="blue">acquisitions</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">integration</font>     will require <font color="blue">significant</font> efforts from each company</td>
    </tr>
    <tr>
      <td>We may find it <font color="blue">difficult</font>     to  integrate  the  <font color="blue">operations</font>  as  <font color="blue">personnel may leave</font> and licensees,     <font color="blue">distributors</font> or <font color="blue">suppliers may terminate</font> their <font color="blue">arrangements</font> or <font color="blue">demand amended</font>     terms to these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">management</font> may have their     <font color="blue">attention diverted while trying</font> to integrate these companies</td>
    </tr>
    <tr>
      <td>If we are not     able  to <font color="blue">successfully</font> integrate the <font color="blue">operations</font>, we may not realize the     anticipated benefits of these <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>If we fail to implement our <font color="blue">restructure</font> plans <font color="blue">successfully</font>, our business     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In fiscal year 2005, we merged the <font color="blue">operations</font> of ResMed     Germany  and  MAP  into  a single operating unit as part of our <font color="blue">German     </font><font color="blue">restructure</font>  plan</td>
    </tr>
    <tr>
      <td>We  will  continue to monitor the progress of this     <font color="blue">restructure</font> and adjust our business strategies and <font color="blue">personnel accordingly</font> to     achieve maximum efficiencies, cost savings and success</td>
    </tr>
    <tr>
      <td>If we are not able     to integrate the <font color="blue">operations</font> <font color="blue">successfully</font>, we may not fully realize the     anticipated benefits of the <font color="blue">restructure</font></td>
    </tr>
    <tr>
      <td>- 22 -     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>We are subject to <font color="blue">various risks</font> relating to <font color="blue"><font color="blue">international</font> <font color="blue">activities</font></font> that     <font color="blue">could affect</font> our overall <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> substantially all     of our <font color="blue">products outside</font> the US and sell a <font color="blue">significant</font> portion of our     products  in  non-US  markets</td>
    </tr>
    <tr>
      <td>Sales outside <font color="blue">North and Latin America     </font>accounted for <font color="blue">approximately</font> 48prca and 49prca of our <font color="blue">net revenues</font> in the years     ended June 30, 2006 and 2005, respectively</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">sales within</font>     these <font color="blue">areas will account</font> for <font color="blue">approximately</font> 50prca of our <font color="blue">net revenues</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales outside</font> of <font color="blue">North America </font>and our <font color="blue">operations</font> in     Europe, Australia and Asia are subject to several <font color="blue">difficult</font>ies and risks     that are separate and <font color="blue">distinct from</font> those we face in our US <font color="blue">operations</font>,     including:           •   <font color="blue"><font color="blue">fluctuation</font>s</font> in <font color="blue">currency exchange rates</font>;           •   tariffs and other <font color="blue">trade barriers</font>;           •   <font color="blue">compliance with foreign medical</font> device <font color="blue">manufacturing</font> <font color="blue">regulations</font>;           •   reduction in <font color="blue"><font color="blue">third party</font> payer <font color="blue">reimbursement</font></font> for our products;           •   <font color="blue">inability</font> to obtain import licenses;           •   changes in <font color="blue">trade policies</font> and in US and foreign tax policies;           •   possible changes in export or import <font color="blue">restrictions</font>; and           •   the <font color="blue">modification</font> or <font color="blue">introduction</font> of other <font color="blue">government</font>al policies with     <font color="blue">potentially adverse effects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and private insurance plans may not <font color="blue">adequately</font> reimburse patients     for our products, <font color="blue">which could</font> result in <font color="blue">reductions</font> in sales or selling     prices for our products</td>
    </tr>
    <tr>
      <td>Our ability to sell our products depends in     large part on the extent to <font color="blue">which <font color="blue">reimbursement</font></font> for the cost of our products     will be available from <font color="blue">government</font> health administration authorities, private     health  insurers and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">third party</font> payers</font> are     <font color="blue">increasingly</font>  <font color="blue">challenging</font>  the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td>Therefore, even if a product is approved for marketing, we cannot     assure you that <font color="blue"><font color="blue">reimbursement</font> will</font> be allowed for the product, that the     <font color="blue"><font color="blue">reimbursement</font> amount</font> will be adequate or, that the <font color="blue"><font color="blue">reimbursement</font> amount</font>,     even if initially adequate, will not <font color="blue">subsequently</font> be reduced</td>
    </tr>
    <tr>
      <td>For example,     in some markets, such as Spain, France and Germany, <font color="blue">government</font> <font color="blue">reimbursement</font>     is <font color="blue">currently available</font> for purchase or rental of our <font color="blue">products but</font> is subject     to <font color="blue">constraints such as price controls</font> or unit <font color="blue">sales limitations</font></td>
    </tr>
    <tr>
      <td>In other     markets,  such as Australia and the United Kingdom, there is currently     limited  or  no  <font color="blue">reimbursement</font> for devices that treat sleep-disordered     breathing  <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">future <font color="blue">legislation</font></font> or regulation     <font color="blue">concerning</font> the <font color="blue">healthcare industry</font> or <font color="blue">third party</font> or <font color="blue">government</font>al coverage     and  <font color="blue">reimbursement</font>,  <font color="blue">particularly</font>  <font color="blue">legislation</font>  or <font color="blue">regulation limiting</font>     consumers’ <font color="blue">reimbursement</font> rights, may harm our business</td>
    </tr>
    <tr>
      <td>As we continue to develop <font color="blue">new products</font>, those <font color="blue">products will <font color="blue">generally</font></font> not     qualify for <font color="blue">reimbursement</font>, if at all, until they are approved for marketing</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we sell our <font color="blue">products primarily</font> to <font color="blue">home healthcare</font>     dealers and to <font color="blue">sleep clinics</font></td>
    </tr>
    <tr>
      <td>We do not file claims and bill <font color="blue">government</font>al     programs and other <font color="blue"><font color="blue">third party</font> payers</font> directly for <font color="blue">reimbursement</font> for our     products</td>
    </tr>
    <tr>
      <td>However, we are still subject to laws and <font color="blue">regulations</font> relating to     <font color="blue">government</font>al <font color="blue">reimbursement</font> programs, <font color="blue">particularly</font> <font color="blue">Medicaid and Medicare</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">reimbursement</font> for our products, our <font color="blue">customers depend</font> in part     on  <font color="blue">reimbursement</font>  by <font color="blue">government</font> and <font color="blue">private health insurers</font> for other     products</td>
    </tr>
    <tr>
      <td>Any proposed <font color="blue">reductions</font> in <font color="blue">reimbursement</font>, if they occur, may have     a material <font color="blue">impact on</font> our customers</td>
    </tr>
    <tr>
      <td>Any material <font color="blue">impact on</font> our customers may     <font color="blue"><font color="blue">indirectly</font> affect</font> our sales to those customers, or the <font color="blue">collectibility</font> of     <font color="blue">receivables</font> we have from those customers</td>
    </tr>
    <tr>
      <td>Failure to comply with anti-kickback and fraud <font color="blue">regulations</font> could result in     substantial  penalties  and  changes in our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     particular, the federal Anti-Kickback Law <font color="blue">prohibits persons from knowingly</font>     and <font color="blue">willfully soliciting</font>, receiving, offering or <font color="blue">providing remuneration</font>,                                         - 23 -     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>directly or <font color="blue">indirectly</font>, to <font color="blue">induce either</font> the referral of an individual, or     the furnishing, recommending or arranging for a good or service, for which     <font color="blue">payment may</font> be made under a <font color="blue">federal healthcare program such as</font> the Medicare     and Medicaid programs</td>
    </tr>
    <tr>
      <td>The US <font color="blue">government</font> has interpreted this <font color="blue">law broadly</font>     to  apply  to  the marketing and <font color="blue">sales <font color="blue">activities</font></font> of <font color="blue">manufacture</font>rs and     <font color="blue">distributors</font> like us</td>
    </tr>
    <tr>
      <td>Many states and other <font color="blue">government</font>s have <font color="blue">adopted laws</font>     similar to the federal Anti-Kickback Law</td>
    </tr>
    <tr>
      <td>We are also subject to other     federal and state <font color="blue">fraud laws applicable</font> to <font color="blue">payment from</font> any <font color="blue">third party</font>     payer</td>
    </tr>
    <tr>
      <td>These <font color="blue">laws prohibit persons from knowingly</font> and <font color="blue">willfully filing false</font>     claims or executing a scheme to defraud any <font color="blue">healthcare benefit program</font>,     including private <font color="blue"><font color="blue">third party</font> payers</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">laws may apply</font> to <font color="blue">manufacture</font>rs     and  <font color="blue">distributors</font>  who  provide  information  on coverage, coding, and     <font color="blue">reimbursement</font> of their products to persons who do bill <font color="blue"><font color="blue">third party</font> payers</font></td>
    </tr>
    <tr>
      <td>Any  violation of these laws and <font color="blue">regulations</font> could result in civil and     criminal  penalties  (including  fines),  <font color="blue">increased legal expenses</font> and     <font color="blue">exclusions</font> from <font color="blue">government</font>al <font color="blue">reimbursement</font> programs, all of <font color="blue">which could</font> have     a  material adverse effect upon our business, <font color="blue">financial condition</font>s and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with Food and Drug Administration, or FDA, and other <font color="blue">regulations</font>     is an expensive and time-consuming process, and any failure to <font color="blue">comply could</font>     result in substantial penalties</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various federal</font>,     state,  local  and  <font color="blue">international</font>  <font color="blue">regulations</font>  regarding our business     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Failure to comply with these <font color="blue">regulations</font> could result in, among     other  things, recalls of our products, substantial fines and criminal     charges against us or against our employees</td>
    </tr>
    <tr>
      <td>Furthermore, our products could     be subject to recall if the FDA or we determine, for any reason, that our     products are not safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Any recall or other <font color="blue">regulatory</font> action     <font color="blue">could increase</font> our costs, damage our reputation, affect our ability to     <font color="blue">supply customers with</font> the quantity of products they require and <font color="blue">materially</font>     affect our operating results</td>
    </tr>
    <tr>
      <td>Product sales, <font color="blue">introduction</font>s or <font color="blue">modification</font>s may be delayed or <font color="blue">canceled as</font>     a result of FDA <font color="blue">regulations</font> or similar foreign <font color="blue">regulations</font>, <font color="blue">which could</font>     cause our sales and profits to decline</td>
    </tr>
    <tr>
      <td>Before we can market or sell a     new medical device in the <font color="blue">United States</font>, we must obtain FDA clearance, which     can be a lengthy and time-consuming process</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> receive clearance     from  the  FDA  to  market  our  products  in  the <font color="blue"><font color="blue">United States</font> </font>under     Section 510(k) of the Federal Food, Drug, and Cosmetic Act or our products     are exempt from the 510(k) clearance process</td>
    </tr>
    <tr>
      <td>However, if the FDA <font color="blue">disagrees with us</font> and     requires us to submit new 510(k) notifications for <font color="blue">modification</font>s to our     <font color="blue">existing products</font>, we may be required to <font color="blue">stop marketing</font> the <font color="blue">products while</font>     the FDA reviews the 510(k) notification</td>
    </tr>
    <tr>
      <td>Any new product <font color="blue">introduction</font> or existing product <font color="blue">modification</font> could be     subjected  to  a lengthier, more rigorous FDA <font color="blue">examination process</font></td>
    </tr>
    <tr>
      <td>For     example, in <font color="blue">certain cases</font> we may need to <font color="blue">conduct clinical trials</font> of a new     product before submitting a 510(k) notice</td>
    </tr>
    <tr>
      <td>Additionally, we may be required     to obtain <font color="blue">premarket approvals</font> for our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">requirements</font> of these     more rigorous processes could delay product <font color="blue">introduction</font>s and increase the     <font color="blue">costs associated with</font> FDA compliance</td>
    </tr>
    <tr>
      <td><font color="blue">Marketing </font>and sale of our products     outside the <font color="blue"><font color="blue">United States</font> </font>are also subject to <font color="blue">regulatory</font> clearances and     approvals, and if we fail to obtain these <font color="blue">regulatory</font> approvals, our sales     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any <font color="blue">new products</font> we develop will receive required     <font color="blue">regulatory</font> approvals from US or foreign <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>Off-label  marketing  of  our  products  could  result  in substantial     penalties</td>
    </tr>
    <tr>
      <td><font color="blue">Clearance </font>under Section 510(k) only permits us to market our     products for the uses indicated on the <font color="blue">labeling cleared by</font> the FDA We may     <font color="blue">request additional label indications</font> for our <font color="blue">current products</font>, and the FDA     may deny those <font color="blue">requests outright</font>, require <font color="blue">additional expensive clinical data</font>     to support any <font color="blue">additional indications</font> or <font color="blue">impose limitations on</font> the intended     use  of  any  <font color="blue">cleared products as</font> a condition of clearance</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA     </font>determines that we have marketed our products for off-label use, we could be     subject to fines, injunctions or other penalties</td>
    </tr>
    <tr>
      <td>- 24 -     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Disruptions in the supply of <font color="blue"><font color="blue">components</font> from</font> our <font color="blue">single source suppliers</font>     could result in a <font color="blue">significant</font> reduction in sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We     purchase  uniquely  <font color="blue">configured <font color="blue">components</font></font> for our <font color="blue">devices from various</font>     suppliers, including some who are single-source suppliers for us</td>
    </tr>
    <tr>
      <td>We cannot     assure  you that a <font color="blue">replacement</font> supplier would be able to configure its     <font color="blue">components</font> for our devices on a <font color="blue">timely basis</font> or, in the <font color="blue">alternative</font>, that we     would be able to <font color="blue">reconfigure</font> our devices to integrate the <font color="blue">replacement</font> part</td>
    </tr>
    <tr>
      <td>A reduction or halt in <font color="blue">supply while</font> a <font color="blue">replacement</font> supplier <font color="blue">reconfigure</font>s its     <font color="blue">components</font>, or while we <font color="blue">reconfigure</font> our devices for the <font color="blue">replacement</font> part,     <font color="blue">would limit</font> our ability to <font color="blue">manufacture</font> our devices, <font color="blue">which could</font> result in a     <font color="blue">significant</font> reduction in sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     our <font color="blue">inventories would</font> be adequate to meet our production needs during any     <font color="blue">prolonged interruption</font> of supply</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">intellectual property</font> may</font> not protect our products, and/or our products     <font color="blue">may infringe on</font> the <font color="blue"><font color="blue">intellectual property</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We     rely  on  a  <font color="blue">combination</font>  of patents, trade secrets and non-disclosure     <font color="blue">agreements</font> to protect our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in     part, on our ability to obtain and maintain <font color="blue"><font color="blue">United States</font> </font>and foreign patent     protection for our products, their uses and our processes to preserve our     trade secrets and to operate <font color="blue">without infringing on</font> the <font color="blue">proprietary rights</font> of     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have a number of <font color="blue">pending patent <font color="blue">applications</font></font>, and we do     not know whether any <font color="blue">patents will issue from</font> any of these <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We     do not know whether any of the claims in our <font color="blue">issued patents</font> or pending     <font color="blue">applications</font>  will  <font color="blue">provide us with</font> any <font color="blue">significant</font> protection against     <font color="blue">competitive products</font> or otherwise be <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td>Legal standards     regarding the validity of patents and the proper scope of their claims are     <font color="blue">still evolving</font>, and there is <font color="blue">no <font color="blue">consistent</font> law</font> or policy regarding the valid     breadth of claims</td>
    </tr>
    <tr>
      <td>Additionally, there may be <font color="blue">third party</font> patents, patent     <font color="blue">applications</font> and other <font color="blue">intellectual property</font> relevant to our products and     <font color="blue">technology which</font> are not known to us and that block or <font color="blue">compete with</font> our     products</td>
    </tr>
    <tr>
      <td>We face the risks that:           •   <font color="blue">third parties</font> will infringe our <font color="blue"><font color="blue">intellectual property</font> rights</font>;           •   our non-disclosure <font color="blue">agreements</font> will be breached;           •   we will not have <font color="blue">adequate remedies</font> for <font color="blue">infringement</font>;           •   our <font color="blue">trade secrets will become known</font> to or <font color="blue">independently</font> developed by     our <font color="blue">competitors</font>; or           •   <font color="blue">third parties</font> will be <font color="blue">issued patents</font> that <font color="blue">may prevent</font> the sale of our     products or require us to license and pay fees or royalties in order for us     to be able to market some of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to <font color="blue">enforce patents issued</font> to us, to protect our     <font color="blue">proprietary rights</font>, or to defend <font color="blue">third party</font> claims that we have infringed     upon <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>For example, we are <font color="blue">currently appealing</font>     the decision of a court in Germany that <font color="blue">entered judgment</font> in favor of certain     plaintiffs that had claimed they should be listed as co-inventors on two of     our  German patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">prosecution</font> of patent     claims, including these pending claims, <font color="blue">as well as participation</font> in other     inter-party proceedings, can be expensive and time consuming, even in those     instances in which the outcome is favorable to us</td>
    </tr>
    <tr>
      <td>If the outcome of any     <font color="blue">litigation</font>  or <font color="blue">proceeding <font color="blue">brought against us</font></font> were adverse, we could be     subject to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font>, could be required to     obtain licenses from <font color="blue">third parties</font>, could be forced to <font color="blue">design around</font> the     patents  at  issue or could be required to <font color="blue">cease sales</font> of the affected     products</td>
    </tr>
    <tr>
      <td>A <font color="blue">license may</font> not be <font color="blue">available at</font> all or on <font color="blue">commercially</font> viable     terms,  and  we  may  not  be  able  to redesign our products to avoid     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Additionally, the laws regarding the <font color="blue">enforceability</font> of patents     vary from country to country, and we <font color="blue">cannot assure</font> you that any patent     issues we face will be uniformly resolved, or that local laws will provide     us with <font color="blue">consistent</font> rights and benefits</td>
    </tr>
    <tr>
      <td>- 25 -     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>We are subject to <font color="blue"><font color="blue">potential product</font> <font color="blue">liability</font></font> claims that may exceed the     scope  and  amount of our <font color="blue">insurance coverage</font>, which would expose us to     <font color="blue">liability</font> for uninsured claims</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">potential product</font>     <font color="blue">liability</font> claims as a result of the design, <font color="blue">manufacture</font> and marketing of     <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Any product <font color="blue">liability</font> claim <font color="blue">brought against us</font>, with or     without  merit,  could result in the increase of our product <font color="blue">liability</font>     <font color="blue">insurance rates</font></td>
    </tr>
    <tr>
      <td>In addition, we would have to pay any <font color="blue">amount awarded by</font> a     court in excess of our <font color="blue">policy limits</font></td>
    </tr>
    <tr>
      <td>Our insurance policies have various     <font color="blue">exclusions</font>, and thus we may be subject to a product <font color="blue">liability</font> claim for     which we have <font color="blue">no <font color="blue">insurance coverage</font></font>, in which case, we may have to pay the     <font color="blue">entire amount</font> of any award</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">insurance coverage</font>     will be adequate or that all claims <font color="blue"><font color="blue">brought against us</font> will</font> be <font color="blue">covered by</font>     our insurance</td>
    </tr>
    <tr>
      <td>Insurance varies in cost and can be <font color="blue">difficult</font> to obtain, and     we <font color="blue">cannot assure</font> you that we will be able to obtain insurance in the future     on terms acceptable to us or at all</td>
    </tr>
    <tr>
      <td>A successful product <font color="blue">liability</font> claim     <font color="blue">brought against us</font> in excess of our <font color="blue">insurance coverage</font>, if any, may require     us to pay substantial amounts, <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td>We  are  subject  to  tax  audits  by  <font color="blue">various <font color="blue">tax authorities</font></font> in many     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>From time to time we may be <font color="blue">audited by</font> the <font color="blue">tax authorities</font>     and are still subject to an ongoing German tax audit</td>
    </tr>
    <tr>
      <td>Any <font color="blue">final assessment</font>     resulting from this <font color="blue">audit could</font> result in material changes to our past or     future taxable income, tax payable or <font color="blue">deferred tax assets</font>, and could require     us to <font color="blue">pay penalties</font> and interest that could <font color="blue">materially</font> <font color="blue">adversely</font> affect our     financial results</td>
    </tr>
    <tr>
      <td>Our quarterly operating results are subject to <font color="blue">fluctuation</font> for a variety of     reasons</td>
    </tr>
    <tr>
      <td>Our operating results have, from time to time, <font color="blue">fluctuated on</font> a     <font color="blue">quarterly basis</font> and may be subject to similar <font color="blue"><font color="blue">fluctuation</font>s</font> in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">fluctuation</font>s</font> may result from a number of factors, including:           •   the <font color="blue">introduction</font> of <font color="blue">new products</font> by us or our <font color="blue">competitors</font>;           •   the <font color="blue">geographic mix</font> of <font color="blue">product sales</font>;           •   the success of our <font color="blue">marketing efforts</font> in <font color="blue">new regions</font>;           •   changes in <font color="blue">third party</font> <font color="blue">reimbursement</font>;           •   timing of <font color="blue">regulatory</font> clearances and approvals;           •   timing of orders by <font color="blue">distributors</font>;           •   <font color="blue">expenditures incurred</font> for research and <font color="blue">development</font>;           •   <font color="blue">competitive pricing</font> in <font color="blue">different</font> regions;           •   <font color="blue">seasonality</font>;           •   the cost and effect of promotional and <font color="blue">marketing programs</font>;           •   the effect of <font color="blue">foreign currency</font> transaction gains or losses; and           •   other <font color="blue">activities</font> of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our quarterly operating results may cause the <font color="blue">market price</font>     of our <font color="blue">common stock</font> to fluctuate</td>
    </tr>
    <tr>
      <td>If a natural or man-made disaster strikes our <font color="blue">manufacturing</font> <font color="blue">facilities</font>, we     will be unable to <font color="blue">manufacture</font> our products for a substantial amount of time     and our sales and <font color="blue">profitability</font> will decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> and the     <font color="blue">manufacturing</font> equipment we use to produce our <font color="blue">products would</font> be costly to     replace and could require substantial lead-time to repair or replace</td>
    </tr>
    <tr>
      <td>The     <font color="blue">facilities</font> may be <font color="blue">affected by</font> natural or man-made disasters and in the event     they were <font color="blue">affected by</font> a disaster, we would be forced to rely on <font color="blue">third party</font>     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Although we believe we possess <font color="blue">adequate insurance</font> for damage     to our property and the <font color="blue">disruption</font> of our business from casualties, such     <font color="blue">insurance may</font> not be sufficient to cover all of our <font color="blue">potential losses</font> and may     not continue to be available to us on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>- 26 -     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>Delaware law, provisions in our charter and our <font color="blue">shareholder rights</font> plan     could make it <font color="blue">difficult</font> for another company to acquire us</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of     our  <font color="blue">certificate</font>  of  incorporation may have the effect of delaying or     preventing changes in control or <font color="blue">management</font> which might be <font color="blue">beneficial</font> to us     or our security holders</td>
    </tr>
    <tr>
      <td>In particular, our board of <font color="blue">directors</font> is divided     into three classes, serving for staggered three-year terms</td>
    </tr>
    <tr>
      <td>Because of this     classification  it  will require at least two annual meetings to elect     <font color="blue">directors</font> <font color="blue">constituting</font> a majority of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Additionally,  our board of <font color="blue">directors</font> has the authority to issue up to     2cmam000cmam000 shares of <font color="blue">preferred stock</font> and to determine the price, rights,     preferences, privileges and <font color="blue">restrictions</font>, including <font color="blue">voting rights</font>, of those     shares  without  <font color="blue">further vote</font> or <font color="blue">action by</font> the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Under our     <font color="blue">stockholder rights</font> plan, we have <font color="blue">also issued purchase rights</font> to the holders     of our <font color="blue">common stock</font> that entitle those holders to purchase our Series A     Junior  Participating  Preferred  Stock  at  a discount, under certain     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of our <font color="blue">common stock</font> will be subject     to, and may be <font color="blue">adversely</font> <font color="blue">affected by</font>, the rights of the holders of any     <font color="blue">preferred stock</font> that may be issued in the future</td>
    </tr>
    <tr>
      <td>The issuance of preferred     stock may have the effect of delaying, deferring or preventing a change in     control, may discourage bids for our <font color="blue">common stock</font> at a <font color="blue">premium over</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font> and may <font color="blue">adversely</font> affect the <font color="blue">market price</font>     of our <font color="blue">common stock</font> and the voting and other rights of the holders of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>You may not be able to enforce the judgments of US <font color="blue">courts against</font> some of     our assets or officers and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>A substantial portion of our assets     are  <font color="blue">located outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Additionally, two of our eight     <font color="blue">directors</font> and three of our <font color="blue">seven executive officers reside outside</font> the     <font color="blue">United States</font>, <font color="blue">along with</font> all or a substantial portion of the assets of     these persons</td>
    </tr>
    <tr>
      <td>As a result, it may not be possible for investors to enforce     judgments of US courts relating to any <font color="blue">liabilities under</font> US securities     <font color="blue">laws against</font> our assets, those persons or their assets</td>
    </tr>
    <tr>
      <td>In addition, we have     <font color="blue">been advised by</font> our <font color="blue">Australian </font>counsel that some doubt exists as to the     ability of investors to pursue claims <font color="blue">based on</font> US securities <font color="blue">laws against</font>     these assets or these persons in <font color="blue">Australian </font>courts</td>
    </tr>
  </tbody>
</table>